Your Pressing Questions About Treating Alopecia Areata Answered

Reported by Women's Health Magazine.

Nearly 7 million Americans are living with alopecia areata — and for a long time, most of them were doing it without a single FDA-approved treatment option. That gap has started to close, but the conversation around this condition still hasn't caught up to the medicine. So let's have it.

Alopecia areata is not a cosmetic problem, a stress response, or something you're bringing on yourself. It's a chronic autoimmune disease in which the immune system attacks hair follicles, triggering inflammation that disrupts growth. Board-certified dermatologist Jennifer Soung, MD, who specializes in medical dermatology and clinical research in Santa Ana, California, is direct about the stigma patients carry into her office: "Many patients feel embarrassed because they feel they're being too vain if they care about their hair. This is a medical condition — not a cosmetic condition." Stress can aggravate the disease, she clarifies, but it is not the cause. You are not causing your own hair loss. According to Women's Health Magazine, alopecia areata is rooted in a combination of genetic predisposition and environmental triggers — stress being one of several factors that can surface an underlying vulnerability, not create it.

The Treatment Conversation You Might Not Know to Have

Traditionally, alopecia areata has been managed with oral, topical, or injectable steroids — blunt instruments designed to suppress immune activity broadly, not target the disease specifically. If those haven't worked, or have stopped working, Dr. Soung says it's time to go back to your dermatologist and push for a different conversation. One newer option: LITFULO (ritlecitinib), a once-daily pill from Pfizer approved by the FDA in 2023 for adults and adolescents 12 and older with severe alopecia areata. Unlike steroids, it works by binding to select proteins within immune cells to reduce the specific inflammatory signaling involved in the disease. In clinical trials, 23 percent of patients on LITFULO achieved 80 percent or more scalp hair coverage in just under six months, compared to 1.6 percent on placebo. Hair regrowth is never fast — Dr. Soung is clear that six months is a realistic minimum before visible results — but that data matters for patients who've spent years cycling through options that weren't built for them. As with any medication, LITFULO carries serious potential risks, including increased risk of infection, cancer, cardiovascular events, and blood clots; a full discussion with your dermatologist about your medical history and current medications is essential before starting treatment.

If you're unsure where to begin, start with the right specialist — a board-certified dermatologist with actual alopecia areata experience, not every derm has it. LITFULO's Dermatologist Finder tool exists for exactly this reason. Go in with your treatment goals articulated. "Tell me about your concerns and what your treatment goals are," Dr. Soung says — that's how she calibrates severity and maps a path forward. A Doctor Discussion Guide is also available at LITFULO.com to help you prepare.

Alopecia areata is unpredictable, emotionally exhausting, and still widely misunderstood — but the treatment landscape has shifted, and you deserve to know every option on the table.

Read the original at Women's Health Magazine.